Panacea Journal of Medical Sciences

---

Rare occurrence: Colitis induced by nab-paclitaxel in metastatic pancreatic cancer treatment - A case report

Full Text PDF Share on Facebook Share on Twitter

---

Case Report

Author Details : Vishal Kulkarni, Madhusoodan M Gonenavar*, Sandeep Kumbar, Sudhanshu Shukla, Tejashree Sridhar

Volume : 14, Issue : 3, Year : 2024

Article Page : 892-895

https://10.18231/j.pjms.2024.159

Suggest article by email

---

Abstract

Nab-Paclitaxel is a standard first-line treatment for metastatic pancreatic adenocarcinoma. While this therapy has shown promise, it can lead to rare but severe adverse effects, including colitis. We report a case of a 63-year-old patient with metastatic pancreatic adenocarcinoma treated with nab-paclitaxel who developed severe colitis after the first cycle. symptoms included abdominal pain, vomiting, diarrhoea, and melena. Laboratory, biopsy, and sigmoidoscopy reports were suggestive of drug-induced colitis. Treatment involved antibiotics, anti-inflammatory drugs, and supportive care.This case underscores the importance of monitoring patients for colitis during nab-paclitaxel-based chemotherapy and considering treatment modification if necessary. Early intervention is critical in managing this rare but potentially serious complication.
 

Keywords: Chemotherapy, Colitis, Nab­Paclitaxel, Sigmoidoscopy

How to cite : Kulkarni V, Gonenavar M M, Kumbar S, Shukla S, Sridhar T, Rare occurrence: Colitis induced by nab-paclitaxel in metastatic pancreatic cancer treatment - A case report. Panacea J Med Sci 2024;14(3):892-895

Copyright © 2024 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)